JSH-23
JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS) -stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation[1].
Product Specifications
CAS Number
749886-87-1
UNSPSC
12352005
Hazard Statement
H302, H318, H400
Target
NF-κB
Type
Reference compound
Related Pathways
NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/JSH-23.html
Purity
99.92
Solubility
DMSO : ≥ 56 mg/mL
Smiles
NC1=CC(C)=CC=C1NCCCC2=CC=CC=C2
Molecular Formula
C16H20N2
Molecular Weight
240.34
Precautions
H302, H318, H400
References & Citations
[1]Shin HM, et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett. 2004 Jul 30;571 (1-3) :50-4.|[2]Kumar A, et al. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab. 2011 Aug;13 (8) :750-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NF-κB
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC043786-500 1x 500 µL
AKT1 (Prognostic Marker for Neuroendocrine Tumors) (rAKT1/2491), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
